Photo by ari_spada from unsplash
Low‐density lipoprotein (LDL) apheresis is a treatment option for patients with unhealed chronic limb‐threatening ischemia (CLTI) after revascularization. The newly developed AS‐25 is a direct hemoperfusion‐type apheresis device that differs… Click to show full abstract
Low‐density lipoprotein (LDL) apheresis is a treatment option for patients with unhealed chronic limb‐threatening ischemia (CLTI) after revascularization. The newly developed AS‐25 is a direct hemoperfusion‐type apheresis device that differs from conventional LDL apheresis therapy and is designed to specifically adsorb both LDL‐C and fibrinogen. We evaluate the efficacy and safety of AS‐25.
Keywords:
threatening ischemia;
apheresis;
chronic limb;
limb threatening;
low density;
density lipoprotein
Journal Title: Therapeutic Apheresis and Dialysis
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Therapeutic Apheresis and Dialysis
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!